Oral probiotics as anti-infectious immune response stimulators in the respiratory tract

Abstract


This review analyzes whether it is expedient to use oral probiotics for the stimulation of immune response against pathogens in the respiratory tract. It considers a relationship between mucosal microbial colonization in different biotopes of the body and mucosal immunity in the respiratory tract. The principal and terminological controversial issues of colonic dysbiosis and the possibilities of using the medicines and products containing live commensals/symbionts to correct microbiota disturbances are examined. There are data on the degree of resistance and resilience of the colonic microbial community exposed to destabilizing factors, antibiotics in particular. The properties of probiotics that have been proven to enhance host response against pathogens and the phenomena that characterize these probiotics as immunomodifiers and distinguish them from other immunostimulating/immunomodulating agents are described. Criteria for choosing effective and safe oral probiotics to stimulate an immune response in the respiratory tract are formulated. Finally, we review the data on the clinical and immunomodulatory effects of dietary supplement containing a combination of three probiotic strains (Lactobacillus gasseri PA 16/8, Bifidobacterium bifidum MF 20/5 and Bifidobacterium longum SP 07/3) with vitamins and minerals as an agent to prevent and reduce the severity of acute and recurrent respiratory tract infections.

References

  1. Notter RH. Lung surfactants: basic science and clinical applications. New York: Marcel Dekker; 2000.
  2. Rogers GB, Shaw D, Marsh RL Carroll MP, Serisier DJ, Bruce KD. Republished: Respiratory microbiota: addressing clinical questions, informing clinical practice. Postgrad Med J. 2015; 91(1078):463-470. doi: 10.1136/postgradmedj-2014-205826rep.
  3. Калюжин О.В. Безопасность и физиологичность действия пробиотиков как средств иммунокоррекции. Российский аллергологический журнал. 2013;(3):45-56.
  4. Калюжин О.В. Возможности использования пробиотиков для укрепления противоинфекционной защиты в свете иммуногомеостатической роли микробиоты. Эффективная фармакотерапия. 2013;27-2:12-25.
  5. Калюжин О.В. Пробиотики как современные средства укрепления противоинфекционной защиты: миф или реальность? Русский медицинский журнал. 2012;28:1395-1401.
  6. Qin J, Li R, Raes J, Arumugam M, Burgdorf KS, Manichanh C, Nielsen T, Pons N, Levenez F, Yamada T, Mende DR, Li J, Xu J, Li S, Li D, Cao J, Wang B, Liang H, Zheng H, Xie Y, Tap J, Lepage P, Bertalan M, Batto JM, Hansen T, Le Paslier D, Linneberg A, Nielsen HB, Pelletier E, Renault P, Sicheritz-Ponten T, Turner K, Zhu H, Yu C, Li S, Jian M, Zhou Y, Li Y, Zhang X, Li S, Qin N, Yang H, Wang J, Brunak S, Doré J, Guarner F, Kristiansen K, Pedersen O, Parkhill J, Weissenbach J; MetaHIT Consortium, Bork P, Ehrlich SD, Wang J. A human gut microbial gene catalogue established by metagenomic sequencing. Nature. 2010; 464(7285):59-65. doi: 10.1038/nature08821.
  7. The NIH HMP Working Group, Peterson J, Garges S, Giovanni M, McInnes P, Wang L, Schloss JA, Bonazzi V, McEwen JE, Wetterstrand KA, Deal C, Baker CC, Di Francesco V, Howcroft TK, Karp RW, Lunsford RD, Wellington CR, Belachew T, Wright M, Giblin C, David H, Mills M, Salomon R, Mullins C, Akolkar B, Begg L, Davis C, Grandison L, Humble M, Khalsa J, Little AR, Peavy H, Pontzer C, Portnoy M, Sayre MH, Starke-Reed P, Zakhari S, Read J, Watson B, Guyer M. The NIH HumanMicrobiome Project. Genome Res. 2009;19(12):2317-2323. doi: 10.1101/gr.096651.109.
  8. Carding S, Verbeke K, Vipond DT, Corfe BM, Owen LJ. Dysbiosis of the gut microbiota in disease. Microbial Ecology in Health & Disease. 2015;26:26191. doi:http://dx.doi.org/10.3402/mehd.v26.26191.
  9. Shade A, Peter H, Allison SD, Baho DL, Berga M, Bürgmann H, Huber DH, Langenheder S, Lennon JT, Martiny JB, Matulich KL, Schmidt TM, Handelsman J. Fundamentals of Microbial Community Resistance and Resilience. Front Microbiol. 2012;3:417. doi: 10.3389/fmicb.2012.00417.
  10. Nami Y, Haghshenas B, Abdullah N, Barzegari A, Radiah D, Rosli R, Yari Khosroushahi A. Probiotics or antibiotics: future challenges in medicine. J Med Microbiol. 2015;64(2):137-146. doi: 10.1099/jmm.0.078923-0.
  11. Fouhy F, Guinane CM, Hussey S, Wall R, Ryan CA, Dempsey EM, Murphy B, Ross RP, Fitzgerald GF, Stanton C, Cotter PD. High-Throughput Sequencing Reveals the Incomplete, Short-Term Recovery of Infant Gut Microbiota following Parenteral Antibiotic Treatment with Ampicillin and Gentamicin. Antimicrobial Agents Chemother. 2012;56(11):5811-5820. doi: 10.1128/AAC.00789-12.
  12. Bush K. Alarming β-lactamase-mediated resistance in multidrug-resistant Enterobacteriaceae. Curr Opin Microbiol. 2010;13(5):558-564. doi: 10.1016/j.mib.2010.09.006.
  13. Donabedian SM, Thal LA, Hershberger E, Perri MB, Chow JW, Bartlett P, Jones R, Joyce K, Rossiter S, Gay K, Johnson J, Mackinson C, Debess E, Madden J, Angulo F, Zervos MJ. Molecular Characterization of Gentamicin-Resistant Enterococci in the United States: Evidence of Spread from Animals to Humans through Food. J Clin Microbiol. 2003;41(3):1109-1113. doi: 10.1128/JCM.41.3.1109-1113.2003.
  14. Weisser M, Oostdijk EA, Willems RJ, Bonten MJ, Frei R, Elzi L, Halter J, Widmer AF, Top J. Dynamics of ampicillin-resistant Enterococcus faecium clones colonizing hospitalized patients: data from a prospective observational study. BMC Infecti Dis. 2012;12:68. doi: 10.1186/1471-2334-12-68.
  15. Hevia A, Delgado S, Sánchez B, Margolles A. Molecular players involved in the interaction between beneficial bacteria and the immune system. Front Microbiol. 2015;6:1285. doi: 10.3389/fmicb.2015.01285.
  16. Mu C, Yang Y, Zhu W. Crosstalk between the immune receptors and gut microbiota. Curr Protein Pept Sci. 2015;16(7):622-631. doi: 10.2174/1389203716666150630134356.
  17. Sánchez B, Gueimonde M, Peña AS, Bernardo D. Intestinal microbiota as modulators of the immune system. J Immunol Res. 2015;2015:159094. doi: 10.1155/2015/159094.
  18. Калюжин О.В. Феномен тренированного иммунитета и механизмы действия неспецифических иммуномодуляторов. Российский аллергологический журнал. 2015;4:45-51.
  19. Johansson MA, Sjögren YM, Persson J-O, Nilsson C, Sverremark-Ekström E. Early colonization with a group of lactobacilli decreases the risk for allergy at five years of age despite allergic heredity. Zimmer J, ed. PLoS ONE. 2011;6(8):e23031. doi: 10.1371/journal.pone.0023031.
  20. Marschan E, Kuitunen M, Kukkonen K, Poussa T, Sarnesto A, Haahtela T, Korpela R, Savilahti E, Vaarala O. Probiotics in infancy induce protective immune profiles that are characteristic for chronic low-grade inflammation. Clin Exper Allergy. 2008;38:611-618. doi: 10.1111/j.1365-2222.2008.02942.x.
  21. Mandel DR, Eichas K, Holmes J. Bacillus coagulans: a viable adjunct therapy for relieving symptoms of rheumatoid arthritis according to a randomized, controlled trial. BMC Complement Altern Med. 2010;10:1. doi: 10.1186/1472-6882-10-1.
  22. De los Angeles Pineda M, Thompson SF, Summers K, de Leon F, Pope J, Reid G. A randomized, double-blinded, placebo-controlled pilot study of probiotics in active rheumatoid arthritis. Medical Science Monitor: Int Medical J Exper Clin Res. 2011;17(6):CR347-CR354. doi: 10.12659/MSM.881808.
  23. Inohara N, Ogura Y, Fontalba A, Gutierrez O, Pons F, Crespo J, Fukase K, Inamura S, Kusumoto S, Hashimoto M, Foster SJ, Moran AP, Fernandez-Luna JL, Nuñez G. Host recognition of bacterial muramyl dipeptide mediated through NOD2: Implications for Crohn’s disease. J Biol Chem. 2003;278(8):5509-5512. doi: 10.1074/jbc.C200673200.
  24. Ярилин А.А. Основы иммунологии. М.: Медицина; 1999.
  25. FAO/WHO. Probiotics in Food: Health and Nutritional Properties and Guidelines for Evaluation. FAO Food and Nutrition Paper 85. Rome: Food and Agriculture Organization of the United Nations and World Health Organization; 2006. Available at: ftp://ftp.fao.org/docrep/fao/009/a0512e/a0512e00.pdf. Accessed 28 December, 2015.
  26. Sanders ME, Akkermans LMA, Haller D, Hammerman C, Heimbach J, Hörmannsperger G, Huys G, Levy DD, Lutgendorff F, Mack D, Phothirath P, Solano-Aguilar G, Vaughan E. Safety assessment of probiotics for human use. Gut Microbes. 2010;1(3):164-185. doi: 10.4161/gmic.1.3.12127.
  27. Franz CM, Huch M, Abriouel H, Holzapfel W, Gálvez A. Enterococci as probiotics and their implications in food safety. Int J Food Microbiol. 2011;151(2):125-140. doi: 10.1016/j.ijfoodmicro.2011.08.014.
  28. López P, González-Rodríguez I, Gueimonde M, Margolles A, Suárez A. Immune response to Bifidobacterium bifidum strains support Treg/Th17 plasticity. PLoS One. 2011;6(9)e24776. doi: 10.1371/journal.pone.0024776.
  29. Dong H, Rowland I, Yaqoob P. Comparative effects of six probiotic strains on immune function in vitro. Br J Nutr. 2012;108(3):459-470. doi: 10.1017/S0007114511005824.
  30. Yamamoto T, Kishida Y, Ishida T, Hanedano M. Effect of lactic acid bacteria on intestinally decomposed substance producing bacteria of human source. Basics Clin. 1986;20(14):123.
  31. de Vrese M, Winkler P, Rautenberg P, Harder T, Noah C, Laue C, Ott S, Hampe J, Schreiber S, Heller K, Schrezenmeir J. Effect of Lactobacillus gasseri PA 16/8, Bifidobacterium bifidum MF 20/5, Bifidobacterium longum SP 07/3 on common cold episodes: Double blind, randomized, controlled trial. ClinNutrition. 2005;24:481-491. doi: 10.1016/j.clnu.2005.02.006.
  32. Wrinkler P, de Vrese M, Laue Ch, Schrezenmeir J. Effect of a dietary supplement containing probiotic bacteria plus vitamins and minerals on common cold infections and cellular immune parameters. Int J Clin Pharmacol Ther. 2005;43(7):318-326. doi: 10.5414/cpp43318.
  33. Taverniti V, Guglielmetti S. The immunomodulatory properties of probiotic microorganisms beyond their viability (ghost probiotics: proposal of paraprobiotic concept). Genes Nutrition. 2011;6(3):261-274. doi: 10.1007/s12263-011-0218-x.
  34. Дюков Л.А., Шульга И.А. Взаимосвязь иммунологических расстройств и нарушений микробиоценоза кишечника у больных хроническим тонзиллитом. Российская оториноларингология. 2008;3:98-103. Доступно по: http://entru.org/files/j_rus_LOR_4_2008.pdf. Ссылка активна на 28.12.2015.
  35. Калюжин О.В., Бунятян К.А., Инвияева Е.В., Ананьев Д.П., Матвеев Д.А., Митрохин С.Д., Винницкий Л.И. Бион 3 в профилактике послеоперационных осложнений и коррекции расстройств иммунной системы и кишечной микробиоты у больных колоректальным раком. Курский научно-практический вестник «Человек и его здоровье». 2013;1:67-74.

Statistics

Views

Abstract - 84

PDF (Russian) - 24

Cited-By


Article Metrics

Metrics Loading ...

Refbacks

  • There are currently no refbacks.

Copyright (c) 2020 Kalyuzhin O.V., Afanasyev S.S., Bykov A.S.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Novoslobodskaya str 31c4., Moscow, 127005, Russian Federation

Managing Editor:

 

© 2018 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies